Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 3/20 | 0.81 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.81 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.81 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.54 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | CPA3 | P15088 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519045 | 1.00 | SLC1A1 (0.81) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL31269773 | 0.92 | SLC1A1 (0.69) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL2265548 | 0.89 | SLC1A1 (1.00) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL8377822 | 0.89 | SLC1A1 (1.00) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL130817 | 0.89 | SLC1A1 (1.00) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL133913 | 0.89 | SLC1A1 (1.00) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL8959957 | 0.88 | SLC1A1 (0.96) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL16494899 | 0.86 | SLC1A1 (0.81) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| SCHEMBL29386512 | 0.85 | SLC1A1 (0.84) | SLC1A1SLC1A3SLC1A2ALPIPKM | |
| Ethylene Glycol SCHEMBL27596923 | 0.85 | SLC1A1 (0.90) | SLC1A1SLC1A3SLC1A2ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596558-A | polymer shell nanocapsules | UNIV SANTIAGO COMPOSTELA | 2014-02-19 | — | — | CN | disclosed |
| US-20100145018-A1 | Lipid-Polymer-Conjugates | ASTELLAS PHARMA EUROPE BV (NL) | 2010-06-10 | — | — | US | disclosed |
| EP-1392755-B1 | LIPID-POLYMER-CONJUGATES COMPOSITIONS | ASTELLAS PHARMA EUROP B V (NL) | 2008-12-03 | — | — | EP | disclosed |
| CN-1308375-C | Lipid-polymer-conjugates compsns. | YAMANOUCHI EUROP BV (NL) | 2007-04-04 | — | — | CN | disclosed |
| EP-1392756-B1 | LIPID-POLYMER-CONJUGATES | ASTELLAS PHARMA EUROP B V (NL) | 2007-02-14 | — | — | EP | disclosed |
| CN-1271116-C | Lipid-polymer-conjugates | YAMANOUCHI EUROP BV (NL) | 2006-08-23 | — | — | CN | disclosed |
| CN-1602326-A | Lipid-polymer-conjugates | YAMANOUCHI EUROP BV (NL) | 2005-03-30 | — | — | CN | disclosed |
| US-20040254352-A1 | Lipid-polymer-conjugates | YAMANOUCHI EUROPE B.V. (NL) | 2004-12-16 | — | — | US | disclosed |
| US-20040241222-A1 | Lipid-polymer-conjugates compositions | ASTELLAS PHARMA EUROPE B.V. (NL) | 2004-12-02 | — | — | US | disclosed |
| CN-1520435-A | Lipid-polymer-conjugates compsns. | ֮��ŷ������˾ | 2004-08-11 | — | — | CN | disclosed |
| CN-1148227-C | Therapeutical compound and its application | 博立迈生物技术开发（深圳）有限公司 | 2004-05-05 | — | — | CN | disclosed |
| EP-1392756-A2 | LIPID-POLYMER-CONJUGATES | Yamanouchi Europe B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| EP-1392755-A1 | LIPID-POLYMER-CONJUGATES COMPOSITIONS | YAMANOUCHI EUROPE B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098951-A2 | LIPID-POLYMER-CONJUGATES | YAMANOUCHI EUROPE B.V. (NL) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098952-A1 | LIPID-POLYMER-CONJUGATES COMPOSITIONS | YAMANOUCHI EUROPE B.V. (NL) | 2002-12-12 | — | — | WO | disclosed |
| CN-1310025-A | Therapeutical compound and its application | AMERICAN FINNIE BIO SCIENCE IN (US) | 2001-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145018-A1 | Lipid-Polymer-Conjugates | PARG, GLUL, PHOSPHO1 | SLC1A1 77/4885SLC1A3 35/4885SLC1A2 93/4885 |
| US-20040254352-A1 | Lipid-polymer-conjugates | PARG, GLUL, PARN | SLC1A1 89/4885SLC1A3 41/4885SLC1A2 116/4885 |
| US-20040241222-A1 | Lipid-polymer-conjugates compositions | PHOSPHO1, PARG, GLUL | SLC1A1 63/4885SLC1A3 46/4885SLC1A2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.